• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.

作者信息

Ahmadi P, Alsdorf W, Leypoldt L, Kosch R, Schaefers C, Gagelmann N, Ayuk F, Kron F, Weisel K

机构信息

Controlling University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Bone Marrow Transplant. 2025 Apr;60(4):538-540. doi: 10.1038/s41409-024-02505-x. Epub 2025 Jan 22.

DOI:10.1038/s41409-024-02505-x
PMID:39843583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11971040/
Abstract
摘要

相似文献

1
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.T细胞重定向作为复发多发性骨髓瘤护理的新标准：对德国住院能力、经济负担和基础设施要求的影响
Bone Marrow Transplant. 2025 Apr;60(4):538-540. doi: 10.1038/s41409-024-02505-x. Epub 2025 Jan 22.
2
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.在既往接受过或未接受过 T 细胞重定向治疗的复发/难治性多发性骨髓瘤患者中，使用 teclistamab 后的 CRS 模式。
Blood Adv. 2024 Jun 25;8(12):3038-3044. doi: 10.1182/bloodadvances.2024012724.
3
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.序贯 T 细胞重定向疗法可使复发/难治性骨髓瘤患者获得深度和持久缓解。
Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923.
4
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.嵌合抗原受体T细胞：复发/难治性多发性骨髓瘤的现状与未来方向综述
Front Oncol. 2024 Aug 8;14:1455464. doi: 10.3389/fonc.2024.1455464. eCollection 2024.
5
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.患者对多发性骨髓瘤及其治疗的看法：来自英国、法国和德国患者访谈的定性证据。
Patient. 2021 Sep;14(5):613-623. doi: 10.1007/s40271-021-00501-7. Epub 2021 Mar 9.
6
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法治疗骨髓瘤：我们现在处于什么位置，以及需要什么才能将嵌合抗原受体 T 细胞推进到更早的治疗线？美国移植和细胞治疗学会专家小组意见。
Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.
7
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!异基因造血干细胞移植后多发性骨髓瘤的 T 细胞重定向治疗：当治愈失败时！
Br J Haematol. 2024 Mar;204(3):753-754. doi: 10.1111/bjh.19267. Epub 2023 Dec 18.
8
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.MajesTEC-1研究中复发/难治性多发性骨髓瘤患者免疫适应性与对替卡泊单抗反应的相关性
Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823.
9
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.替西罗莫司联合卡非佐米、地塞米松治疗复发/难治性多发性骨髓瘤患者的临床管理。
Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):665-693.e14. doi: 10.1016/j.clml.2024.05.003. Epub 2024 May 15.
10
Immunotherapy in multiple myeloma: when, where, and for who?多发性骨髓瘤的免疫治疗：何时、何地、针对谁？
Curr Opin Oncol. 2020 Nov;32(6):664-671. doi: 10.1097/CCO.0000000000000677.

引用本文的文献

1
Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures.多发性骨髓瘤免疫失调内在驱动因素的生物信息学分析，以阐明免疫表型并发现预后基因特征。
Sci Rep. 2025 May 5;15(1):15662. doi: 10.1038/s41598-025-00074-7.

本文引用的文献

1
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.关于ide-cel或标准治疗方案用于复发或难治性多发性骨髓瘤患者的KarMMa-3研究的通俗易懂的总结。
Future Oncol. 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954. Epub 2024 Apr 23.
2
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.与 CD3×CD20 双特异性抗体治疗相关毒性管理的共识建议。
Blood. 2024 Apr 18;143(16):1565-1575. doi: 10.1182/blood.2023022432.
3
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.嵌合抗原受体T细胞（CAR-T）疗法门诊给药与住院给药对血液系统癌症患者临床、经济和人文结局的影响：一项系统文献综述
Cancers (Basel). 2023 Dec 7;15(24):5746. doi: 10.3390/cancers15245746.
4
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
5
Treatment horizon in multiple myeloma.多发性骨髓瘤的治疗前景。
Eur J Haematol. 2022 Nov;109(5):425-440. doi: 10.1111/ejh.13840. Epub 2022 Sep 18.
6
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.LocoMMotion 研究：一项针对复发和/或难治性多发性骨髓瘤患者的真实临床实践中现行标准治疗的前瞻性、非干预性、多国研究。
Leukemia. 2022 May;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2. Epub 2022 Mar 24.
7
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
8
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.对 CD38 靶向单克隆抗体治疗耐药的多发性骨髓瘤患者的结局。
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.